Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 241

1.

No evidence that panic attacks are associated with the white coat effect in hypertension.

Davies SJ, Jackson PR, Ramsay LE, Ghahramani P, Palmer RL, Hippisley-Cox J.

J Clin Hypertens (Greenwich). 2003 Mar-Apr;5(2):145-52.

2.

Drug intolerance due to nonspecific adverse effects related to psychiatric morbidity in hypertensive patients.

Davies SJ, Jackson PR, Ramsay LE, Ghahramani P.

Arch Intern Med. 2003 Mar 10;163(5):592-600.

PMID:
12622606
3.

Coronary and cardiovascular risk estimation in uncomplicated mild hypertension. A comparison of risk assessment methods.

Yikona JI, Wallis EJ, Ramsay LE, Jackson PR.

J Hypertens. 2002 Nov;20(11):2173-82.

PMID:
12409955
4.

Cardiovascular and coronary risk estimation in hypertension management.

Wallis EJ, Ramsay LE, Jackson PR.

Heart. 2002 Sep;88(3):306-12. Review. No abstract available.

5.

Magnetic resonance angiography for the diagnosis of renal artery stenosis: a meta-analysis.

Tan KT, van Beek EJ, Brown PW, van Delden OM, Tijssen J, Ramsay LE.

Clin Radiol. 2002 Jul;57(7):617-24. Review.

PMID:
12096862
6.

First-line treatment for hypertension.

Jackson PR, Ramsay LE; United States JNC VI and British Hypertension Society Guideline; International WHO/ISH Guideline.

Eur Heart J. 2002 Feb;23(3):179-82. No abstract available.

PMID:
11792127
7.

Statins for primary prevention: at what coronary risk is safety assured?

Jackson PR, Wallis EJ, Haq IU, Ramsay LE.

Br J Clin Pharmacol. 2001 Oct;52(4):439-46.

8.

Dysfunctional breathing and asthma. Panic disorder needs to be considered.

Davies SJ, Jackson PR, Ramsay LE.

BMJ. 2001 Sep 15;323(7313):631; author reply 631-2. No abstract available.

9.

Prevention of stroke and transient ischaemic attack.

Jackson PR, Wallis EJ, Ramsay LE.

Lancet. 2001 Sep 1;358(9283):762. No abstract available.

PMID:
11556348
10.

Population implications of lipid lowering for prevention of coronary heart disease: data from the 1995 Scottish health survey.

Haq IU, Ramsay LE, Wallis EJ, Isles CG, Ritchie LD, Jackson PR.

Heart. 2001 Sep;86(3):289-95.

11.

Is coronary risk an accurate surrogate for cardiovascular risk for treatment decisions in mild hypertension? A population validation.

Wallis EJ, Ramsay LE, Haq IU, Ghahramani P, Jackson PR.

J Hypertens. 2001 Apr;19(4):691-6.

PMID:
11330871
12.

Aspirin for primary prevention. Treatment policy should be based on all trial evidence, not subgroup analysis.

Ramsay LE, Sanmuganathan PS, Wallis EJ, Jackson PR.

BMJ. 2000 Dec 9;321(7274):1472. No abstract available.

13.
14.

Optimal age for starting lipid lowering treatment. Adjusted date do not justify a lower optimal age.

Jackson PR, Wallis EJ, Ramsay LE.

BMJ. 2000 Sep 9;321(7261):637-8. No abstract available.

PMID:
11023329
15.

Comparison of methods of estimating coronary risk. Authors did not use latest version of Sheffield table.

Wallis EJ, Ramsay LE, Yikona JI, Jackson PR.

BMJ. 2000 Jul 15;321(7254):175-6. No abstract available.

16.

Debate: at what level of coronary heart disease risk should a statin be prescribed?

Jackson PR, Ramsay LE.

Curr Opin Lipidol. 2000 Aug;11(4):357-61. Review.

PMID:
10945716
17.

Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population.

Wallis EJ, Ramsay LE, Ul Haq I, Ghahramani P, Jackson PR, Rowland-Yeo K, Yeo WW.

BMJ. 2000 Mar 11;320(7236):671-6. Erratum in: BMJ 2000 Apr 15;320(7241):1034.

18.

Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods.

Haq IU, Ramsay LE, Jackson PR, Wallis EJ.

QJM. 1999 Jul;92(7):379-85.

PMID:
10627887
19.

Implication of recent trials with b-hydroxy-b-methylglutaryl coenzyme A reductase inhibitors for hypertension management.

Haq IU, Wallis EJ, Jackson PR, Yeo WW, Ramsay LE.

J Hypertens. 1999 Nov;17(11):1641-6.

PMID:
10608479
20.

Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients.

Yeo KR, Yeo WW, Wallis EJ, Ramsay LE.

Br J Clin Pharmacol. 1999 Oct;48(4):610-5.

21.

Association of panic disorder and panic attacks with hypertension.

Davies SJ, Ghahramani P, Jackson PR, Noble TW, Hardy PG, Hippisley-Cox J, Yeo WW, Ramsay LE.

Am J Med. 1999 Oct;107(4):310-6.

PMID:
10527031
22.

British Hypertension Society guidelines for hypertension management 1999: summary.

Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, Poulter NR, Russell G.

BMJ. 1999 Sep 4;319(7210):630-5. No abstract available.

23.
24.

Thiazide diuretics in hypertension.

Ramsay LE.

Clin Exp Hypertens. 1999 Jul-Aug;21(5-6):805-14. Review.

PMID:
10423103
26.

Cholesterol screening and management guidelines. Policy based on Sheffield table fully satisfies authors' criteria.

Ramsay LE, Wallis EJ, Haq IU, Jackson PR, Yeo WW.

BMJ. 1999 Apr 24;318(7191):1140-1. No abstract available.

PMID:
10366266
27.

Coronary risk assessment methods and cholesterol lowering.

Ramsay LE, Wallis EJ, Haq IU, Jackson PR.

Lancet. 1999 Mar 27;353(9158):1095; author reply 1096-7. No abstract available.

PMID:
10199369
28.

Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Haq IU, Wallis EJ, Yeo WW, Jackson PR, Ramsay LE.

JAMA. 1999 Feb 3;281(5):414; author reply 417-9. No abstract available.

PMID:
9952191
29.

Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.

Wallis EJ, Ramsay LE, Hettiarachchi J.

Clin Pharmacol Ther. 1998 Oct;64(4):439-49.

PMID:
9797801
30.

Cholestanol and survival with simvastatin. More data are needed.

Wallis EJ, Williamson R, Ramsay LE, Yeo WW, Jackson PR.

BMJ. 1998 Oct 31;317(7167):1252-3. No abstract available.

31.

Statins for prevention of stroke.

Wallis EJ, Ramsay LE, Yeo WW, Jackson PR.

Lancet. 1998 Sep 12;352(9131):909-10. No abstract available.

PMID:
9743018
32.

Use of statins. Sheffield table is useful.

Ramsay LE, Wallis EJ, Haq IU, Williamson R, Yeo WW, Jackson PR.

BMJ. 1998 Aug 15;317(7156):473-4. No abstract available.

33.

The rationale for differing national recommendations for the treatment of hypertension.

Ramsay LE, Wallis EJ, Yeo WW, Jackson PR.

Am J Hypertens. 1998 Jun;11(6 Pt 2):79S-88S; discussion 95S-100S. Review.

PMID:
9655567
34.

Protein binding of aspirin and salicylate measured by in vivo ultrafiltration.

Ghahramani P, Rowland-Yeo K, Yeo WW, Jackson PR, Ramsay LE.

Clin Pharmacol Ther. 1998 Mar;63(3):285-95.

PMID:
9542472
35.

Drug therapy for coronary heart disease: the Sheffield table.

Ramsay LE, Wallis EJ, Haq IU, Yeo WW, Jackson PR.

Lancet. 1998 Feb 7;351(9100):443-4. No abstract available.

PMID:
9482325
36.

Use of statins. Evidence on effectiveness is stronger for statins than for other treatments.

Wallis EJ, Ramsay LE, Yeo WW, Jackson PR, Pickin M, Haq IU.

BMJ. 1997 Dec 13;315(7122):1618-9. No abstract available.

37.

Drug therapy for coronary heart disease: the Sheffield table.

Wallis EJ, Ramsay LE, Jackson PR, Yeo WW, Williamson R.

Lancet. 1997 Dec 20-27;350(9094):1852. No abstract available.

PMID:
9428275
38.

Panic disorder, anxiety and depression in resistant hypertension--a case-control study.

Davies SJ, Ghahramani P, Jackson PR, Hippisley-Cox J, Yeo WW, Ramsay LE.

J Hypertens. 1997 Oct;15(10):1077-82.

PMID:
9350581
39.

Pressor and hormonal responses to angiotensin I infusion in healthy subjects of different angiotensin-converting enzyme genotypes.

Chadwick IG, O'Toole L, Morice AH, Yeo WW, Jackson PR, Ramsay LE.

J Cardiovasc Pharmacol. 1997 Apr;29(4):485-9.

PMID:
9156358
40.

Cytochromes P450 mediating the N-demethylation of amitriptyline.

Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT.

Br J Clin Pharmacol. 1997 Feb;43(2):137-44.

41.

Cholesterol and prevention of coronary heart disease.

Haq IU, Jackson PR, Yeo WW, Ramsay LE.

Lancet. 1997 Jan 18;349(9046):210-1. No abstract available.

PMID:
9111570
42.

The hypertension detection and follow-up program: 17 years on.

Ramsay LE.

JAMA. 1997 Jan 8;277(2):167-70. No abstract available.

PMID:
8990345
43.

American College of Physicians guidelines on cholesterol screening.

Haq IU, Jackson PR, Ramsay LE.

Ann Intern Med. 1996 Dec 15;125(12):1010; author reply 1011. No abstract available.

PMID:
8967696
44.

Interpretation of prospective trials in hypertension: do treatment guidelines accurately reflect current evidence?

Ramsay LE, ul Haq I, Yeo WW, Jackson PR.

J Hypertens Suppl. 1996 Dec;14(5):S187-94. Review.

PMID:
9120677
45.

The Sheffield table for primary prevention of coronary heart disease: corrected.

Ramsay LE, Haq IU, Jackson PR, Yeo WW.

Lancet. 1996 Nov 2;348(9036):1251. No abstract available.

PMID:
8898071
46.

No relation between angiotensin-converting enzyme gene polymorphism and dermal response to bradykinin in healthy subjects.

Chadwick IG, Kraskiewicz M, Yeo WW, Higgins KS, Jackson PR, Ramsay LE.

Clin Sci (Lond). 1996 Nov;91(5):617-20.

PMID:
8964127
47.

Lipid-lowering for prevention of coronary heart disease: what policy now?

Ul Haq I, Ramsay LE, Pickin DM, Yeo WW, Jackson PR, Payne JN.

Clin Sci (Lond). 1996 Oct;91(4):399-413. Erratum in: Clin Sci (Colch) 1996 Dec;91(6):773-4.

PMID:
8983865
48.

Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table.

Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN.

Lancet. 1996 Aug 10;348(9024):387-8. No abstract available. Erratum in: Lancet. 1996 Nov 2;348(9036):1251.

PMID:
8709740
49.

Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease.

Haq IU, Jackson PR, Yeo WW, Ramsay LE.

Lancet. 1995 Dec 2;346(8988):1467-71.

PMID:
7490996
50.

Resolution of ACE inhibitor cough: changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance-P.

Yeo WW, Chadwick IG, Kraskiewicz M, Jackson PR, Ramsay LE.

Br J Clin Pharmacol. 1995 Nov;40(5):423-9.

Supplemental Content

Loading ...
Support Center